|Table of Contents|

Research progress of diffuse large B-cell lymphoma with TP53 gene abnormality

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 22
Page:
4241-4245
Research Field:
Publishing date:

Info

Title:
Research progress of diffuse large B-cell lymphoma with TP53 gene abnormality
Author(s):
SUN Rong1; LI Zijian2
1.The First Clinical Medicine College of Lanzhou University,Gansu Lanzhou 730000,China;2.Department of Hematology,the First Hospital of Lanzhou University，Gansu Lanzhou 730000，China.
Keywords:
diffuse large B-cell lymphoma; abnormal TP53 gene; combination therapy with new drugs
PACS:
R733.4
DOI:
10.3969/j.issn.1672-4992.2023.22.028
Abstract:
Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous aggressive malignant tumor with many influencing factors.Among them,TP53 mutation is considered to be an independent factor for the poor prognosis of DLBCL,which often indicates that DLBCL is not sensitive to first-line immunochemotherapy,prone to it manifests as refractory or relapsed,and it cannot obtain survival benefit through intensive chemotherapy regimens such as DA-EPOACH-R.At present,the exploration of the pathogenesis of DLBCL in the form of TP53 gene abnormality,as well as the mechanism of treatment resistance and the treatment of DLBCL with TP53 gene abnormality is still going on.Existing studies have shown that the addition of some new drugs,such as HDAC inhibitors alone or in combination,and new therapeutic strategies,such as CAR-T cell therapy,have opened up new avenues for the treatment of DLBCL with TP53 mutations.Although some of these strategies have shown initial improvement effects,the actual benefit and safety of the disease are still being further explored.

References:

［1］ LEVINE AJ.p53:800 million years of evolution and 40 years of discovery［J］.Nat Rev Cancer,2020,20(8):471-480.
［2］ ALAM MM,FERMIN JM,KNACKSTEDT M,et al.Everolimus downregulates STAT3/HIF-1α/VEGF pathway to inhibit angiogenesis and lymphangiogenesis in TP53 mutant head and neck squamous cell carcinoma (HNSCC) ［J］.Oncotarget,2023,14:85-95.
［3］ TEODORO JG,EVANS SK,GREEN MR.Inhibition of tumor angiogenesis by p53:a new role for the guardian of the genome［J］.J Mol Med (Berl),2007,85(11):1175-1186.
［4］ HU J,CAO J,TOPATANA W,et al.Targeting mutant p53 for cancer therapy:direct and indirect strategies［J］.J Hematol Oncol,2021,14(1):157.
［5］ LI L,LI M,WANG X.Cancer type-dependent correlations between TP53 mutations and antitumor immunity［J］.DNA Repair (Amst),2020,88:102785.
［6］ BLAGIH J,BUCK MD,VOUSDEN KH.p53,cancer and the immune response［J］.J Cell Sci,2020,133(5):jcs237453.
［7］ BROWN DW,BEATTY PH,LEWIS JD.Molecular targeting of the most functionally complex gene in precision oncology:p53［J］.Cancers (Basel),2022,14(21):5176.
［8］ CAPACI V,MANTOVANI F,DEL SAL G.Amplifying tumor-stroma communication:An emerging oncogenic function of mutant p53［J］.Front Oncol,2021,10:614230.
［9］ HAMPEL PJ,PARIKH SA.Chronic lymphocytic leukemia treatment algorithm 2022［J］.Blood Cancer J,2022,12(11):161.
［10］ ZHANG C,LIU J,XU D,et al.Gain-of-function mutant p53 in cancer progression and therapy［J］.J Mol Cell Biol,2020,12(9):674-687.
［11］ 时云飞,高子芬,李向红，等.国人弥漫大B细胞淋巴瘤p53表达的判读标准及预后价值探讨［J］.中华血液学杂志,2022,43(12):1010-1015. SHI YF,GAO ZF,LI XH,et al.Interpretation criteria and prognostic value of p53 expression in diffuse large B-cell lymphoma in China ［J］.Chinese Journal of Hematology,2022,43(12):1010-1015.
［12］ MELINO G.Molecular mechanisms and function of the p53 protein family member-p73［J］.Biochemistry (Mosc),2020,85(10):1202-1209.
［13］ IQBAL J,NAUSHAD H,BI C,et al.Genomic signatures in B-cell lymphoma:How can these improve precision in diagnosis and inform prognosis［J］.Blood Rev,2016,30(2):73-88.
［14］ SARKOZY C,HUNG SS,CHAVEZ EA,et al.Mutational landscape of gray zone lymphoma［J］.Blood,2021,137(13):1765-1776.
［15］ YI S,YAN Y,JIN M,et al.Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma［J］.J Clin Invest,2022,132(3):e153283.
［16］ YOUNG KH,LEROY K,MOLLER MB,et al.Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma:an international collaborative study［J］.Blood,2008,112(8):3088-3098.
［17］ ZAINUDDIN N,BERGLUND M,WANDERS A,et al.TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype［J］.Leuk Res,2009,33(1):60-66.
［18］ CHAN A,DOGAN A.Prognostic and predictive biomarkers in diffuse large b-cell lymphoma［J］.Surg Pathol Clin,2019,12(3):699-707.
［19］ XU-MONETTE ZY,WU L,VISCO C,et al.Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP:report from an International DLBCL Rituximab-CHOP Consortium Program Study［J］.Blood,2012,120(19):3986-3996.
［20］ ZHANG X,WU Z,HAO Y,et al.Aberrantly activated APOBEC3B is associated with mutant p53-driven refractory/relapsed diffuse large B-cell lymphoma［J］.Front Immunol,2022,13:888250.
［21］ BERGSTROM EN,LUEBECK J,PETLJAK M,et al.Mapping clustered mutations in cancer reveals APOBEC3 mutagenesis of ecDNA［J］.Nature,2022,602(7897):510-517.
［22］ ZLAMALIKOVA L,MOULIS M,RAVCUKOVA B,et al.Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas［J］.Oncol Rep,2017,38(4):2535-2542.
［23］ ZENZ T,KREUZ M,FUGE M,et al.TP53 mutation and survival in aggressive B cell lymphoma［J］.Int J Cancer,2017,141(7):1381-1388.
［24］ KERBAUY FR,COLLEONI GW,SAAD ST,et al.Detection and possible prognostic relevance of p53 gene mutations in diffuse large B-cell lymphoma.An analysis of 51 cases and review of the literature［J］.Leuk Lymphoma,2004,45(10):2071-2078.
［25］ LACY SE,BARRANS SL,BEER PA,et al.Targeted sequencing in DLBCL,molecular subtypes,and outcomes:a haematological malignancy research network report［J］.Blood,2020,135(20):1759-1771.
［26］ DOBASHI A,TOGASHI Y,TANAKA N,et al.TP53 and OSBPL10 alterations in diffuse large B-cell lymphoma:prognostic markers identified via exome analysis of cases with extreme prognosis［J］.Oncotarget,2018,9(28):19555-19568.
［27］ STOCKLEIN H,SMARDOVA J,MACAK J,et al.Detailed mapping of chromosome 17p deletions reveals HIC1 as a novel tumor suppressor gene candidate telomeric to TP53 in diffuse large B-cell lymphoma［J］.Oncogene,2008,27(18):2613-2625.
［28］ 孙冠星,曹祥山,李青,等.BCL-6、MYC和p53基因异常与弥漫性大B细胞淋巴瘤免疫学亚型及预后的关系［J］.中华医学遗传学杂志,2012,29(5):576-581. SUN GX,CAO XS,LI Q,et al.Relationship between abnormal BCL-6,MYC and p53 genes and immunological subtypes and prognosis of diffuse large B-cell lymphoma ［J］.Chinese Journal of Medical Genetics,2012,29(5):576-581.
［29］ JIA Z,HE J,CEN L,et al.p53 deletion is independently associated with increased age and decreased survival in a cohort of Chinese patients with diffuse large B-cell lymphoma［J］.Leuk Lymphoma,2012,53(11):2182-2185.
［30］ DODERO A,GUIDETTI A,MARINO F,et al.Dose-adjusted EPOCH and rituximab (DA-EPOCH-R) treatment in dual expressor diffuse large B-cell and double/triple hit lymphomas:TP53 mutations influence on clinical outcome［J］.Haematologica,2022,107(5):1153-1162.
［31］ YAN Q,JIANG S,LIU P,et al.Characteristics and management of TP53-mutated diffuse large B-cell lymphoma patients［J］.Cancer Manag Res,2020,12:11515-11522.
［32］ PAN J,TAN Y,DENG B,et al.Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r/r B-ALL children［J］.Leukemia,2020,34(12):3382-3387.
［33］ LOCKE FL，GHOBADI A，JACOBSON CA，et al.Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma（ZUMA-1）：a single-arm，multicentre，phase 1-2 trial［J］.Lancet Oncol,2019,20(1):31-42.
［34］ ABRAMSON JS,PALOMBA ML,GORDON LI,et al.Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL001):a multicentre seamless design study［J］.Lancet,2020,396(10254):839-852.
［35］ SCHUSTER SJ,BISHOP MR,TAM CS,et al.Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma［J］.N Engl J Med,2019,380(1):45-56.
［36］ 郑艳丽.地西他滨联合化疗治疗TP53突变弥漫大B细胞淋巴瘤的生物学及临床研究 ［D］.太原：山西医科大学，2022. ZHENG YL.Biological and clinical study of decitabine combined with chemotherapy in the treatment of diffuse large B-cell lymphoma with TP53 mutation ［D］.Taiyuan:Shanxi Medical University,2022.
［37］ ZHANG MC,FANG Y,XU PP,et al.Clinical efficacy and tumour microenvironment influence of decitabine plus R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma:Phase 1/2 and biomarker study［J］.Clin Transl Med,2021,11(12):e584.
［38］ ZAJA F,SALVI F,ROSSI M,et al.Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma:clinical outcome and correlation with genomic data.A phase 2 study of the Fondazione Italiana Linfomi［J］.Leuk Lymphoma,2018,59(12):2904-2910.
［39］ ASSOULINE SE,NIELSEN TH,YU S,et al.Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma［J］. Blood,2016,128(2):185-194.
［40］ LI Q,HUANG J,OU Y,et al.Progressive diffuse large B-cell lymphoma with TP53 gene mutation treated with chidamide-based chemotherapy［J］.Immunotherapy,2019,11(4):265-272.
［41］ ZHANG MC,FANG Y,WANG L,et al.Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma［J］.Clin Epigenetics,2020,12(1):160.
［42］ LUO C,YU T,YOUNG KH,et al.HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC,BCL2,and TP53 expression［J］.J Zhejiang Univ Sci B,2022,23(8):666-681.

Memo

Memo:
National Natural Science Foundation of China(No.81300427);国家自然科学基金（编号：81300427）;甘肃省兰州市科技计划项目(编号：2020-ZD-68)
Last Update: 1900-01-01